Cardiac conditioning: a review of evolving strategies to reduce ischaemia-reperfusion injury

Kharbanda, Rajesh K.

doi:10.1136/hrt.2009.179101

Cited by 49 publications

(40 citation statements)

References 114 publications

(57 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Результатом данных работ было не только откры-тие самого феномена, но также было доказано, что реваскуляризация миокарда может вызвать реперфу-зионное повреждение, увеличивающее ишемическое [19,20]. В дальнейшем было установлено, что добиться эффекта "кондиционирования" можно не только описанным методом, но и другими, с использованием механических и фармакологиче-ских приемов [19,20].…”

Section: кондиционирование миокарда как защита миокарда от необратимоunclassified

“…В дальнейшем было установлено, что добиться эффекта "кондиционирования" можно не только описанным методом, но и другими, с использованием механических и фармакологиче-ских приемов [19,20].…”

Section: кондиционирование миокарда как защита миокарда от необратимоunclassified

See 1 more Smart Citation

Pharmacological preconditioning. Focus on nicorandil

Gostishchev¹,

Соболева²,

Самко³

et al. 2018

Vrach

View full text Add to dashboard Cite

Section: кондиционирование миокарда как защита миокарда от необратимоunclassified

Pharmacological preconditioning. Focus on nicorandil

Gostishchev¹,

Соболева²,

Самко³

et al. 2018

Vrach

View full text Add to dashboard Cite

“…Tissue damage occurs when the cardiac muscle is starved of oxygen and nutrients due to blocked coronary vessels but yet further damage occurs when the tissue is reperfused with blood in an attempt to restore circulation. 2 The molecular mechanisms of reperfusion injury are not fully understood. Strategies for pre-conditioning cardiac muscle to confer protection against ischemia/reperfusion injury have been known since the mid-1980s.…”

Section: Introductionmentioning

confidence: 99%

Monitoring Changes in the Redox State of Myoglobin in Cardiomyocytes by Raman Spectroscopy Enables the Protective Effect of NO Donors to Be Evaluated

Almohammedi¹,

Kapetanaki²,

Hudson³

et al. 2015

Anal. Chem.

View full text Add to dashboard Cite

Raman microspectroscopy has been used to monitor changes in the redox and ligandcoordination states of the heme complex in myoglobin during the pre-conditioning of ex vivo cardiomyocytes with pharmacological drugs that release nitric oxide (NO). These chemical agents are known to confer protection on heart tissue against ischemia-reperfusion injury.Subsequent changes in the redox and ligand-coordination states during experimental simulations of ischemia and reperfusion have also been monitored. We found that these measurements, in real time, could be used to evaluate the pre-conditioning treatment of cardiomyocytes, and predict the likelihood of cell survival following a potentially-lethal period of ischemia.Evaluation of the pre-conditioning treatment was done at the single-cell level. The binding of NO to myoglobin, giving a 6-coordinate ferrous-heme complex, was inferred from the measured Raman bands of a cardiomyocyte by comparison to pure solution of the protein in the presence of NO. A key change in the Raman spectrum was observed after perfusion of the NO-donor was completed, where if the pre-conditioning treatment was successful then the bands corresponding to the nitrosyl complex were replaced by bands corresponding to metmyoglobin, Mb III . An observation of Mb III bands in the Raman spectrum was made for all the cardiomyocytes that recovered contractile function, whilst the absence of Mb III bands always indicated that the cardiomyocyte would be unable to recover contractile function, following the simulated conditions of ischemia and reperfusion in these experiments.3

show abstract

“…79 Strategies to protect against reperfusion injury remain high on the research agenda and have been the subject of recent review. 80 In one study the effect of erythropoietin was tested based on beneficial experi-mental effects for reducing infarct size. 81 However, the study was negative, with patients randomised to erythropoietin (50 000 IU) before primary PCI showing an increased incidence of microvascular obstruction and LV dilata tion without reduction in infarct size compared with patients randomised to placebo.…”

Section: Infarct Size and Myocardial Salvagementioning

confidence: 99%

Almanac 2012: Cardiovascular risk scores: The national society journals present selected research that has driven recent advances in clinical cardiology

Meier¹

2013

Srce i krvni sudovi

View full text Add to dashboard Cite

Almanah 2012 serijaPercutaneous coronary intervention versus medical treatment P ercutaneous coronary intervention (PCI) has guide line recommendations for treatment of ST elevation and non-ST elevation myocardial infarction (MI).1 However, its role in stable coronary disease has been the subject of reappraisal following publication of the COURAGE trial, which showed that, in patients receiving optimal medical therapy, PCI does not improve cardiovascular outcomes, while incremental benefits for quality of life disappear by 36 months.2 3 A more recent meta-analysis of eight trials of optimal medical therapy versus PCI involving 7229 patients bears out the COURAGE conclusions by showing no significant differences between the groups with regard to death (9.1% vs 8.9%), non-fatal MI (8.1% vs 8.9%), unplanned revascularisation (30.7% vs 21.4%) and persistent angina (33% vs 29%).4 Drug-eluting stents (DESs) were used in only a minority of these patients and may have reduced the need for further revascularisation while improving symptomatic responses. Nevertheless, the meta-analysis reinforces contemporary guideline advice for optimal medical treatment as the initial treatment for stable angina.5 Whether this will change current practice remains to be seen, but early signs are not encouraging. Thus a US registry analysis of patients undergoing PCI before (n=173416) and after (n=293 795) the COURAGE report showed no change in the proportions receiving optimal medical treatment (43.5% vs 44.7%). 6 PCI versus coronary bypass surgery

show abstract

Cardiac conditioning: a review of evolving strategies to reduce ischaemia-reperfusion injury

Cited by 49 publications

References 114 publications

Pharmacological preconditioning. Focus on nicorandil

Pharmacological preconditioning. Focus on nicorandil

Monitoring Changes in the Redox State of Myoglobin in Cardiomyocytes by Raman Spectroscopy Enables the Protective Effect of NO Donors to Be Evaluated

Almanac 2012: Cardiovascular risk scores: The national society journals present selected research that has driven recent advances in clinical cardiology

Contact Info

Product

Resources

About